Measuring Blood Glucose Using Capillary Blood with Blood Glucose Meters in all Hospitalized Patients
March 30, 2018

Panel Chairperson
Andrew A. Bremer, M.D., Ph.D.

Designated Federal Officer
Patricio G. Garcia, M.P.H.
CDR, USPHS

8:00 a.m. Call to Order
- Conflict of Interest
- Panel Introductions

8:15 a.m. FDA Presentation
- Welcome
- Background
- Data

Questions to FDA

9:30 a.m. Break

9:40 a.m. FDA Questions/Panel Deliberations

12:00 p.m. Lunch

1:00 p.m. Open Public Hearing*

2:00 p.m. FDA Questions/Panel Deliberations Continued

3:45 p.m. Break

3:55 p.m. Summary of Panel Recommendations

4:15 p.m. Adjourn

* Open Public Hearing – Interested persons may present data, information, or views, orally or in writing, on the issue pending before the panel. Scheduled speakers who have requested time to address the panel will speak at this time. After they have spoken, the Chair may ask them to remain if the panel wishes to question them. Then the Chair will recognize unscheduled speakers as time allows. Only the panel may question speakers during the open public hearing.